ATE400812T1 - Zusammensetzungen und verfahren für verstärkte apoptose - Google Patents

Zusammensetzungen und verfahren für verstärkte apoptose

Info

Publication number
ATE400812T1
ATE400812T1 AT03815888T AT03815888T ATE400812T1 AT E400812 T1 ATE400812 T1 AT E400812T1 AT 03815888 T AT03815888 T AT 03815888T AT 03815888 T AT03815888 T AT 03815888T AT E400812 T1 ATE400812 T1 AT E400812T1
Authority
AT
Austria
Prior art keywords
compositions
methods
enhanced apoptosis
apoptosis
matter
Prior art date
Application number
AT03815888T
Other languages
English (en)
Inventor
Wayne Fairbrother
Kurt Deshayes
Saloumeh Fischer
John Flygare
Matthew Franklin
Domagoj Vucic
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE400812T1 publication Critical patent/ATE400812T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT03815888T 2003-02-07 2003-02-07 Zusammensetzungen und verfahren für verstärkte apoptose ATE400812T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/003799 WO2004072641A1 (en) 2003-02-07 2003-02-07 Compositions and methods for enhancing apoptosis

Publications (1)

Publication Number Publication Date
ATE400812T1 true ATE400812T1 (de) 2008-07-15

Family

ID=32867400

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03815888T ATE400812T1 (de) 2003-02-07 2003-02-07 Zusammensetzungen und verfahren für verstärkte apoptose

Country Status (7)

Country Link
EP (1) EP1590666B1 (de)
JP (1) JP4315249B2 (de)
AT (1) ATE400812T1 (de)
AU (3) AU2003216203A1 (de)
CA (1) CA2514316A1 (de)
DE (1) DE60322120D1 (de)
WO (1) WO2004072641A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345081B2 (en) 2004-03-23 2008-03-18 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
KR100926203B1 (ko) 2004-07-02 2009-11-09 제넨테크, 인크. Ｉａｐ의 억제제
MX2007007195A (es) 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
AU2006255084A1 (en) 2005-06-08 2006-12-14 Novartis Ag Organic compounds
WO2007106192A2 (en) 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
WO2007101347A1 (en) * 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics, Inc. composto de ligação de domìnio bir da iap
CN101605786A (zh) 2006-12-19 2009-12-16 健泰科生物技术公司 细胞凋亡抑制剂的咪唑并吡啶抑制剂
NZ598890A (en) 2007-04-30 2013-10-25 Genentech Inc Inhibitors of iap
US8835393B2 (en) 2008-08-02 2014-09-16 Genentech, Inc. Inhibitors of IAP
AU2021399292A1 (en) * 2020-12-17 2023-07-13 Council Of Scientific & Industrial Research Smac mimetics for treatment of cancer, process for preparation and pharmaceutical composition thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
IT1318691B1 (it) * 2000-09-12 2003-08-27 Consiglio Nazionale Ricerche Varianti di proteine allergeniche del gruppo 2 di dermatophagoides.
WO2002026775A2 (en) * 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis
EP1421204A4 (de) * 2001-05-31 2004-12-15 Univ Princeton Iap-bindende peptide und assays zur identifikation von iap-bindenden verbindungen
US20030157522A1 (en) * 2001-11-09 2003-08-21 Alain Boudreault Methods and reagents for peptide-BIR interaction screens

Also Published As

Publication number Publication date
WO2004072641A1 (en) 2004-08-26
JP2006514963A (ja) 2006-05-18
DE60322120D1 (de) 2008-08-21
JP4315249B2 (ja) 2009-08-19
AU2008202756A1 (en) 2008-07-17
EP1590666A1 (de) 2005-11-02
AU2011200426B2 (en) 2014-03-06
AU2011200426A1 (en) 2011-02-24
EP1590666A4 (de) 2006-07-26
EP1590666B1 (de) 2008-07-09
CA2514316A1 (en) 2004-08-26
AU2003216203A1 (en) 2004-09-06

Similar Documents

Publication Publication Date Title
ATE464323T1 (de) Zusammensetzungen und verfahren für die tumor- diagnose und behandlung
SG155947A1 (en) Compositions and methods for the diagnosis and treatment of tumor
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
MXPA05005107A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
WO2005049075A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
MA28909B1 (fr) Quinazolines utiles en tant que modulateurs de canaux ioniques
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
NO20062860L (no) Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
NO20071127L (no) Triazoloftalaziner
WO2005063299A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
WO2005049853A3 (en) Compositions and methods for screening pro-apoptotic compounds
ATE494296T1 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
DE60322120D1 (de) Zusammensetzungen und verfahren für verstärkte apoptose
CY1109992T1 (el) Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα
WO2004096124A3 (en) Compositions and methods for the diagnosis and treatment of tumor
DE60329326D1 (de) Tace inhibitoren
WO2006014335A3 (en) Compositions and methods for treatment of non-hodgkin’s lymphoma
AU2003243381A8 (en) Variants of antithrombin iii
MXPA05008293A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
ATE551054T1 (de) Verfahren und zusammensetzungen zur behandlung von nephrogenem diabetes insipidus
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
DE60326488D1 (de) Zusammensetzungen die eine kombination von diphenylharnstoff impdh-hemmern und apoptose-induzierenden antikrebsmitteln enthalten
WO2006081272A3 (en) Compositions and methods for the diagnosis and treatment of tumor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties